
Rezolute Investor Relations Material
Latest events

AGM 2024
Rezolute

Q3 2025
13 May, 2025

Q2 2025
12 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rezolute Inc
Access all reports
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly those related to chronic glucose imbalances. The company's lead product, RZ358, is a human monoclonal antibody currently in clinical trials aimed at treating congenital hyperinsulinism, a rare pediatric disorder. Additionally, Rezolute is working on RZ402, an oral plasma kallikrein inhibitor, intended for the treatment of diabetic macular edema. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
RZLT
Country
🇺🇸 United States